Global Chronic Lower Back Pain Market Assessment, By Drug Class [Non-steroidal Anti-inflammatory Drugs, Antidepressants, Analgesics, Opioids, Others], By Route of Administration [Oral, Topical, Others], By End-user [Hospital Pharmacies, Retail Pharmacies, Online Pharmacies], By Region, Opportunities and Forecast, 2017-2031F
Global chronic lower back pain market is expected to experience rapid growth due to growing prevalence of lower back pain cases, growing emphasis on drug development for lower back pain management, and growing awareness about pain management.
Home>Industry Reports>Global Chronic Lower Back Pain Market Assessment, Opportunities and Forecast, 2017-2031F
Global chronic lower back pain market is projected to witness a CAGR of 6.22% during the forecast period 2024-2031F, growing from USD 8.02 billion in 2023 to USD 12.99 billion in 2031F. The chronic lower back pain market is anticipated to expand under the impact of driving factors such as the growing prevalence of chronic lower back pain, increasing aging population, sedentary lifestyle, rising prevalence of obesity, advancements in pain management solutions, and increased health consciousness. With the growing corporate industry, people are compelled to remain seated for long working hours, which is the main reason behind many such cases.
Another major factor contributing to its rising prevalence is the increasing geriatric population at higher risk of bodily wear and tear. Chronic pain management is mainly done through drug classes like NSAIDs, analgesics, and opioids, either through oral or topical administration. The advancements in the pharmaceutical industry and increased value share of pain management drugs in recent years are evidence for market expansion.
The major challenge for the expansion of the chronic lower back pain market is the side effects associated with pain management drugs. The increasing popularity of alternative pain management techniques like physical therapies (heat or cold packs, massage, hydrotherapy, and exercise) and psychological therapies (cognitive behavioral therapy, relaxation techniques, and meditation) is a restraining factor for the market. Additionally, stringent regulations regarding the use and prescription of painkiller medicines are a challenge for market expansion. Despite these factors, the market is growing at a faster pace.
In May 2023, Abbott announced that it received the U.S. Food and Drug Administration (FDA) approval for its spinal cord stimulation (SCS) devices meant for the treatment of chronic back pain in people not eligible to receive back surgery, called non-surgical back pain. The approval was given based on the result of the study, which demonstrated that Abbott's proprietary BurstDR SCS technology improved pain levels, and the ability to perform daily activities along with emotional well-being in people with chronic back pain.
Growing Prevalence of Lower Back Pain
The chronic lower back pain market is expected to expand due to the increasing prevalence of spinal disorders and back pain cases. The older population is at a higher risk for spinal disorders due to the natural wear and tear of the spine that comes with aging. It is predicted to result in a significant rise in the number of cases of spinal disorders. Additional factors such as obesity, prolonged periods of sitting for working professionals, poor nutrition, lack of physical activity, and a high frequency of accidents resulting in back pain are expected to contribute to a high incidence of lower back pain. Inherited disorders, inflammations, and infections that damage the spine and tissues in the back are contributing to the growth in the prevalence of lower back pain.
World Spine Care estimated that approximately 1 billion people worldwide suffer from spine pain. Every year, about 72% of the global population is expected to experience back pain, while at any given time, around 59% of people are identified with back pain. Lower back pain is the main cause of disability, and neck pain ranks fourth in the global disability list, as estimated by World Spine Care.
Growing Emphasis on Development of Novel Drugs for Pain Management
The development of novel drugs for pain management has been a growing focus in the medical field. Researchers and pharmaceutical companies are increasingly emphasizing the identification and development of innovative drug targets and delivery systems to improve pain relief. It includes targeting specific receptors, ion channels, or signaling pathways involved in pain transmission and modulation. Additionally, nanotechnology-based drug delivery systems have been explored by manufacturers to enhance the efficacy of analgesic drugs and limit their side effects. Despite the presence of several drugs in the market, the quest for more suitable and safer options to manage lower back pain is further expanding the scope of the market.
For instance, in August 2023, Kenvue Inc. announced the showcasing of its two new products at the PAINWeek Conference 2023. The first product is a topical cream called Tylenol Precise Pain-Relieving Cream which will be launched in the United States first. The second product, which was launched earlier, is called Motrin Dual Action with Tylenol. It is a fixed combination pill containing 250 mg of acetaminophen and 125 mg of ibuprofen in each tablet. The pill provides a dose that supports up to 8 hours of pain relief, which is longer than the dosing provided by Tylenol Extra Strength or Motrin1 single ingredient products that can provide up to 6 hours of relief.
Dominance of Non-steroidal Anti-inflammatory Drugs Segment
Non-steroidal anti-inflammatory drugs (NSAIDs) segment is anticipated to dominate the market owing to its widespread efficacy and popularity. NSAIDs are considered equally effective for musculoskeletal pain, including back pain, and are available over the counter or by prescription. These drugs offer easy accessibility and long-term pain relief and, thus are most commonly prescribed by physicians for treating lower back pain. The low cost of NSAIDs is another factor contributing to its popularity as a pain management solution.
For instance, as per an article in the Journal of Orthopedic Research in February 2023, the research findings provided evidence that the combination of muscle relaxants and NSAIDs (paracetamol) was effective in reducing pain and disability in lower back pain at approximately one week.
Oral Route of Administration to be the Dominating Segment
The oral route of administration for chronic lower back pain is anticipated to be the dominating segment owing to the widespread adoption of oral formulations and the advantages associated with it. The oral route of administration offers improved patient compliance, optimum bioavailability, safety, and low-cost access to medications. From the manufacturer's point of view, oral formulations are easy to prepare and dispense and offer a greater margin of safety, thus, it’s preferred by them. Most of the pain management drugs available in the market are in the form of oral formulations such as tablets, capsules, and others. Oral opioids, such as morphine, hydromorphone, hydrocodone, and oxycodone, can be used for acute or chronic pain.
North America to Dominate the Market
North America is expected to dominate the chronic lower back pain market, owing to the high prevalence of lower back pain cases in countries like the United States and Canada. The high prevalence of lower back pain can be explained by a sedentary lifestyle, high incidence of obesity, unhealthy food habits, and much more. Along with these factors, the strong pharmaceutical infrastructure and high pharmaceutical expenditures strengthen the lead of North American region.
Furthermore, the presence of major key players in the region and the high cost of medications contribute to high-value share. For instance, as per the Health Policy Institute, Washington, almost 65 million Americans have experienced back pain. Out of these, 16 million adults, which is 8 percent of all adults, suffer from persistent or chronic back pain, and the condition limits certain everyday activities. Additionally, back pain is the sixth most expensive condition in the United States, with healthcare and indirect costs amounting to over USD 12 billion each year.
Future Market Scenario (2024 – 2031F)
The management of chronic lower back pain is undergoing a progressive shift towards more personalized and effective treatments. Researchers are focusing on developing targeted approaches, such as the Biomarkers for Evaluating Spine Treatments (BEST) trial, which aim to use individual biomarkers to guide treatment decisions. Promising new therapies, such as tanezumab, which is a monoclonal antibody capable of inhibiting nerve activity, are showing relief for patients with chronic lower back pain. While in the experimental stage, gene therapy is being explored as a potential method to reverse persistent conditions.
Non-opioid alternatives, such as drugs that inhibit proteins in the bloodstream that heighten the sensitivity of cells in the nervous system to pain, are being developed. Exercise and cognitive behavioral therapy have been proven effective in managing chronic lower back pain. New medications will likely take several years to become available, and their safety and efficacy will need to be thoroughly tested before they can be widely adopted.
Report Scope
“Chronic Lower Back Pain Market Assessment, Opportunities, and Forecast, 2017-2031F”, is a comprehensive report by Markets and Data, providing in-depth analysis and qualitative and quantitative assessment of the current state of global chronic lower back pain market, industry dynamics, and challenges. The report includes market size, segmental shares, growth trends, opportunities, and forecast between 2024 and 2031F. Additionally, the report profiles the leading players in the industry mentioning their respective market share, business model, competitive intelligence, etc.
In this report, global chronic lower back pain market has been segmented into the following categories:
· By Drug Class
o Non-steroidal Anti-inflammatory Drugs
o Antidepressants
o Analgesics
o Opioids
o Others
· By Route of Administration
o Oral
o Topical
o Others
· By End-user
o Hospital Pharmacies
o Retail Pharmacies
o Online Pharmacies
· By Region
o North America
o Europe
o Asia-Pacific
o South America
o Middle East and Africa
Key Players Landscape and Outlook
The key players in the chronic lower back pain market include Pfizer Inc., Vertebral Technologies, Inc., Merck & Co., Medtronic plc, Boston Scientific Corporation, and many more players. These players have diverse product portfolios, and a focus on R&D initiatives. Other prominent players include Novartis AG, and Atherna Biosciences. The market is expected to be driven by the increasing aging population with age-related disorders, rising healthcare awareness, and increasing disposable income of consumers. The market is expected to be hampered by the side effects of treatments and the availability of counterfeit drugs.
In September 2023, Boston Scientific offered USD 850 million to acquire back pain ablation tech maker Relievant Medsystems, which is a Minnesota-based provider of an ablation system to treat chronic lower back pain.
Key Players Operating in Global Chronic Lower Back Pain Market are:
· Pfizer Inc
· Vertebral Technologies, Inc.
· Merck & Co.
· Medtronic plc
· Boston Scientific Corporation
· Mesoblast Limited
· SpineThera
· Stayble Therapeutics
· Eli Lilly and Company
· Johnson & Johnson Services, Inc.
Markets and Data report answers the following questions:
· What is the current and future market size of the product/service in question globally or specific to different countries?
· How are the markets divided into different product/service segments and the market size and growth of each segment?
· What is the market potential of different product segments and their investment case?
· How are the markets predicted to develop in the future and what factors will drive or inhibit growth?
· What is the business environment and regulatory landscape specific to the product/service?
If you can't find what you're searching for or have any custom requirements for global chronic lower back pain market, you may approach our team at info@marketsandata.com
Table of Contents
1. Research Methodology
2. Project Scope & Definitions
3. Executive Summary
4. Global Chronic Lower Back Pain Market Outlook, 2017-2031F
4.1. Market Size & Forecast
4.1.1. By Value
4.1.2. By Volume
4.2. By Drug Class
4.2.1.Non-steroidal Anti-inflammatory Drugs
4.2.2.Antidepressants
4.2.3.Analgesics
4.2.4.Opioids
4.2.5.Others
4.3. By Route of Administration
4.3.1.Oral
4.3.2.Topical
4.3.3.Others
4.4. By End-user
4.4.1.Hospital Pharmacies
4.4.2.Retail Pharmacies
4.4.3.Online Pharmacies
4.5. By Region
4.5.1. North America
4.5.2. Europe
4.5.3. Asia-Pacific
4.5.4. South America
4.5.5. Middle East and Africa
4.6. By Company Market Share (%), 2023
5. Global Chronic Lower Back Pain Market Outlook, By Region, 2017-2031F
5.1. North America*
5.1.1.Market Size & Forecast
5.1.1.1. By Value
5.1.1.2. By Volume
5.1.2.By Drug Class
5.1.2.1. Non-steroidal Anti-inflammatory Drugs
5.1.2.2. Antidepressants
5.1.2.3. Analgesics
5.1.2.4. Opioids
5.1.2.5. Others
5.1.3.By Route of Administration
5.1.3.1. Oral
5.1.3.2. Topical
5.1.3.3. Others
5.1.4.By End-user
5.1.4.1. Hospital Pharmacies
5.1.4.2. Retail Pharmacies
5.1.4.3. Online Pharmacies
5.1.5.United States*
5.1.5.1. Market Size & Forecast
5.1.5.1.1. By Value
5.1.5.1.2. By Volume
5.1.5.2. By Drug Class
5.1.5.2.1. Non-steroidal Anti-inflammatory Drugs
5.1.5.2.2. Antidepressants
5.1.5.2.3. Analgesics
5.1.5.2.4. Opioids
5.1.5.2.5. Others
5.1.5.3. By Route of Administration
5.1.5.3.1. Oral
5.1.5.3.2. Topical
5.1.5.3.3. Others
5.1.5.4. By End-user
5.1.5.4.1. Hospital Pharmacies
5.1.5.4.2. Retail Pharmacies
5.1.5.4.3. Online Pharmacies
5.1.6.Canada
5.1.7.Mexico
*All segments will be provided for all regions and countries covered
5.2. Europe
5.2.1.Germany
5.2.2.France
5.2.3.Italy
5.2.4.United Kingdom
5.2.5.Russia
5.2.6.Netherlands
5.2.7.Spain
5.2.8.Turkey
5.2.9.Poland
5.3. Asia-Pacific
5.3.1.India
5.3.2.China
5.3.3.Japan
5.3.4.Australia
5.3.5.Vietnam
5.3.6.South Korea
5.3.7.Indonesia
5.3.8.Philippines
5.4. South America
5.4.1.Brazil
5.4.2.Argentina
5.5. Middle East & Africa
5.5.1.Saudi Arabia
5.5.2.UAE
5.5.3.South Africa
6. Market Mapping, 2023
6.1. By Drug Class
6.2. By Route of Administration
6.3. By End-user
6.4. By Region
7. Macro Environment and Industry Structure
7.1. Demand Supply Analysis
7.2. Import Export Analysis
7.3. Value Chain Analysis
7.4. PESTEL Analysis
7.4.1. Political Factors
7.4.2. Economic System
7.4.3. Social Implications
7.4.4. Technological Advancements
7.4.5. Environmental Impacts
7.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
7.5. Porter’s Five Forces Analysis
7.4.7. Supplier Power
7.4.8. Buyer Power
7.4.9. Substitution Threat
7.4.10. Threat from New Entrant
7.4.11. Competitive Rivalry
8. Market Dynamics
8.1. Growth Drivers
8.2. Growth Inhibitors (Challenges and Restraints)
9. Regulatory Framework and Innovation
9.1. Clinical Trials
9.2. Patent Landscape
9.3. Regulatory Approvals
9.4. Innovations/Emerging Technologies
10. Key Players Landscape
10.1. Competition Matrix of Top Five Market Leaders
10.2. Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
10.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
10.4. SWOT Analysis (For Five Market Players)
11. Pricing Analysis
12. Case Studies
13. Key Players Outlook
13.1. Johnson & Johnson Services, Inc.
13.1.1. Company Details
13.1.2. Key Management Personnel
13.1.3. Products & Services
13.1.4. Financials (As reported)
13.1.5. Key Market Focus & Geographical Presence
13.1.6. Recent Developments
13.2. Pfizer Inc
13.3. Vertebral Technologies, Inc.
13.4. Merck & Co.
13.5. Medtronic plc
13.6. Boston Scientific Corporation
13.7. Mesoblast Limited
13.8. SpineThera
13.9. Stayble Therapeutics
13.10. Eli Lilly and Company
*Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.
14. Strategic Recommendations
15. About Us & Disclaimer
List of Figures
Figure 1. Global Chronic Lower Back Pain Market, By Value, in USD Billion, 2017-2031F
Figure 2. Global Chronic Lower Back Pain Market, By Volume, in Million Units, 2017-2031F
Figure 3. Global Chronic Lower Back Pain Market Share (%), By Drug Class, 2017-2031F
Figure 4. Global Chronic Lower Back Pain Market Share (%), By Route of Administration, 2017-2031F
Figure 5. Global Chronic Lower Back Pain Market Share (%), By End-user, 2017-2031F
Figure 6. Global Chronic Lower Back Pain Market Share (%), By Region, 2017-2031F
Figure 7. North America Chronic Lower Back Pain Market, By Value, in USD Billion, 2017-2031F
Figure 8. North America Chronic Lower Back Pain Market, By Volume, in Million Units, 2017-2031F
Figure 9. North America Chronic Lower Back Pain Market Share (%), By Drug Class, 2017-2031F
Figure 10. North America Chronic Lower Back Pain Market Share (%), By Route of Administration, 2017-2031F
Figure 11. North America Chronic Lower Back Pain Market Share (%), By End-user, 2017-2031F
Figure 12. North America Chronic Lower Back Pain Market Share (%), By Country, 2017-2031F
Figure 13. United States Chronic Lower Back Pain Market, By Value, in USD Billion, 2017-2031F
Figure 14. United States Chronic Lower Back Pain Market, By Volume, in Million Units, 2017-2031F
Figure 15. United States Chronic Lower Back Pain Market Share (%), By Drug Class, 2017-2031F
Figure 16. United States Chronic Lower Back Pain Market Share (%), By Route of Administration, 2017-2031F
Figure 17. United States Chronic Lower Back Pain Market Share (%), By End-user, 2017-2031F
Figure 18. Canada Chronic Lower Back Pain Market, By Value, in USD Billion, 2017-2031F
Figure 19. Canada Chronic Lower Back Pain Market, By Volume, in Million Units, 2017-2031F
Figure 20. Canada Chronic Lower Back Pain Market Share (%), By Drug Class, 2017-2031F
Figure 21. Canada Chronic Lower Back Pain Market Share (%), By Route of Administration, 2017-2031F
Figure 22. Canada Chronic Lower Back Pain Market Share (%), By End-user, 2017-2031F
Figure 23. Mexico Chronic Lower Back Pain Market, By Value, in USD Billion, 2017-2031F
Figure 24. Mexico Chronic Lower Back Pain Market, By Volume, in Million Units, 2017-2031F
Figure 25. Mexico Chronic Lower Back Pain Market Share (%), By Drug Class, 2017-2031F
Figure 26. Mexico Chronic Lower Back Pain Market Share (%), By Route of Administration, 2017-2031F
Figure 27. Mexico Chronic Lower Back Pain Market Share (%), By End-user, 2017-2031F
Figure 28. Europe Chronic Lower Back Pain Market, By Value, in USD Billion, 2017-2031F
Figure 29. Europe Chronic Lower Back Pain Market, By Volume, in Million Units, 2017-2031F
Figure 30. Europe Chronic Lower Back Pain Market Share (%), By Drug Class, 2017-2031F
Figure 31. Europe Chronic Lower Back Pain Market Share (%), By Route of Administration, 2017-2031F
Figure 32. Europe Chronic Lower Back Pain Market Share (%), By End-user, 2017-2031F
Figure 33. Europe Chronic Lower Back Pain Market Share (%), By Country, 2017-2031F
Figure 34. Germany Chronic Lower Back Pain Market, By Value, in USD Billion, 2017-2031F
Figure 35. Germany Chronic Lower Back Pain Market, By Volume, in Million Units, 2017-2031F
Figure 36. Germany Chronic Lower Back Pain Market Share (%), By Drug Class, 2017-2031F
Figure 37. Germany Chronic Lower Back Pain Market Share (%), By Route of Administration, 2017-2031F
Figure 38. Germany Chronic Lower Back Pain Market Share (%), By End-user, 2017-2031F
Figure 39. France Chronic Lower Back Pain Market, By Value, in USD Billion, 2017-2031F
Figure 40. France Chronic Lower Back Pain Market, By Volume, in Million Units, 2017-2031F
Figure 41. France Chronic Lower Back Pain Market Share (%), By Drug Class, 2017-2031F
Figure 42. France Chronic Lower Back Pain Market Share (%), By Route of Administration, 2017-2031F
Figure 43. France Chronic Lower Back Pain Market Share (%), By End-user, 2017-2031F
Figure 44. Italy Chronic Lower Back Pain Market, By Value, in USD Billion, 2017-2031F
Figure 45. Italy Chronic Lower Back Pain Market, By Volume, in Million Units, 2017-2031F
Figure 46. Italy Chronic Lower Back Pain Market Share (%), By Drug Class, 2017-2031F
Figure 47. Italy Chronic Lower Back Pain Market Share (%), By Route of Administration, 2017-2031F
Figure 48. Italy Chronic Lower Back Pain Market Share (%), By End-user, 2017-2031F
Figure 49. United Kingdom Chronic Lower Back Pain Market, By Value, in USD Billion, 2017-2031F
Figure 50. United Kingdom Chronic Lower Back Pain Market, By Volume, in Million Units, 2017-2031F
Figure 51. United Kingdom Chronic Lower Back Pain Market Share (%), By Drug Class, 2017-2031F
Figure 52. United Kingdom Chronic Lower Back Pain Market Share (%), By Route of Administration, 2017-2031F
Figure 53. United Kingdom Chronic Lower Back Pain Market Share (%), By End-user, 2017-2031F
Figure 54. Russia Chronic Lower Back Pain Market, By Value, in USD Billion, 2017-2031F
Figure 55. Russia Chronic Lower Back Pain Market, By Volume, in Million Units, 2017-2031F
Figure 56. Russia Chronic Lower Back Pain Market Share (%), By Drug Class, 2017-2031F
Figure 57. Russia Chronic Lower Back Pain Market Share (%), By Route of Administration, 2017-2031F
Figure 58. Russia Chronic Lower Back Pain Market Share (%), By End-user, 2017-2031F
Figure 59. Netherlands Chronic Lower Back Pain Market, By Value, in USD Billion, 2017-2031F
Figure 60. Netherlands Chronic Lower Back Pain Market, By Volume, in Million Units, 2017-2031F
Figure 61. Netherlands Chronic Lower Back Pain Market Share (%), By Drug Class, 2017-2031F
Figure 62. Netherlands Chronic Lower Back Pain Market Share (%), By Route of Administration, 2017-2031F
Figure 63. Netherlands Chronic Lower Back Pain Market Share (%), By End-user, 2017-2031F
Figure 64. Spain Chronic Lower Back Pain Market, By Value, in USD Billion, 2017-2031F
Figure 65. Spain Chronic Lower Back Pain Market, By Volume, in Million Units, 2017-2031F
Figure 66. Spain Chronic Lower Back Pain Market Share (%), By Drug Class, 2017-2031F
Figure 67. Spain Chronic Lower Back Pain Market Share (%), By Route of Administration, 2017-2031F
Figure 68. Spain Chronic Lower Back Pain Market Share (%), By End-user, 2017-2031F
Figure 69. Turkey Chronic Lower Back Pain Market, By Value, in USD Billion, 2017-2031F
Figure 70. Turkey Chronic Lower Back Pain Market, By Volume, in Million Units, 2017-2031F
Figure 71. Turkey Chronic Lower Back Pain Market Share (%), By Drug Class, 2017-2031F
Figure 72. Turkey Chronic Lower Back Pain Market Share (%), By Route of Administration, 2017-2031F
Figure 73. Turkey Chronic Lower Back Pain Market Share (%), By End-user, 2017-2031F
Figure 74. Poland Chronic Lower Back Pain Market, By Value, in USD Billion, 2017-2031F
Figure 75. Poland Chronic Lower Back Pain Market, By Volume, in Million Units, 2017-2031F
Figure 76. Poland Chronic Lower Back Pain Market Share (%), By Drug Class, 2017-2031F
Figure 77. Poland Chronic Lower Back Pain Market Share (%), By Route of Administration, 2017-2031F
Figure 78. Poland Chronic Lower Back Pain Market Share (%), By End-user, 2017-2031F
Figure 79. South America Chronic Lower Back Pain Market, By Value, in USD Billion, 2017-2031F
Figure 80. South America Chronic Lower Back Pain Market, By Volume, in Million Units, 2017-2031F
Figure 81. South America Chronic Lower Back Pain Market Share (%), By Drug Class, 2017-2031F
Figure 82. South America Chronic Lower Back Pain Market Share (%), By Route of Administration, 2017-2031F
Figure 83. South America Chronic Lower Back Pain Market Share (%), By End-user, 2017-2031F
Figure 84. South America Chronic Lower Back Pain Market Share (%), By Country, 2017-2031F
Figure 85. Brazil Chronic Lower Back Pain Market, By Value, in USD Billion, 2017-2031F
Figure 86. Brazil Chronic Lower Back Pain Market, By Volume, in Million Units, 2017-2031F
Figure 87. Brazil Chronic Lower Back Pain Market Share (%), By Drug Class, 2017-2031F
Figure 88. Brazil Chronic Lower Back Pain Market Share (%), By Route of Administration, 2017-2031F
Figure 89. Brazil Chronic Lower Back Pain Market Share (%), By End-user, 2017-2031F
Figure 90. Argentina Chronic Lower Back Pain Market, By Value, in USD Billion, 2017-2031F
Figure 91. Argentina Chronic Lower Back Pain Market, By Volume, in Million Units, 2017-2031F
Figure 92. Argentina Chronic Lower Back Pain Market Share (%), By Drug Class, 2017-2031F
Figure 93. Argentina Chronic Lower Back Pain Market Share (%), By Route of Administration, 2017-2031F
Figure 94. Argentina Chronic Lower Back Pain Market Share (%), By End-user, 2017-2031F
Figure 95. Asia-Pacific Chronic Lower Back Pain Market, By Value, in USD Billion, 2017-2031F
Figure 96. Asia-Pacific Chronic Lower Back Pain Market, By Volume, in Million Units, 2017-2031F
Figure 97. Asia-Pacific Chronic Lower Back Pain Market Share (%), By Drug Class, 2017-2031F
Figure 98. Asia-Pacific Chronic Lower Back Pain Market Share (%), By Route of Administration, 2017-2031F
Figure 99. Asia-Pacific Chronic Lower Back Pain Market Share (%), By End-user, 2017-2031F
Figure 100. Asia-Pacific Chronic Lower Back Pain Market Share (%), By Country, 2017-2031F
Figure 101. India Chronic Lower Back Pain Market, By Value, in USD Billion, 2017-2031F
Figure 102. India Chronic Lower Back Pain Market, By Volume, in Million Units, 2017-2031F
Figure 103. India Chronic Lower Back Pain Market Share (%), By Drug Class, 2017-2031F
Figure 104. India Chronic Lower Back Pain Market Share (%), By Route of Administration, 2017-2031F
Figure 105. India Chronic Lower Back Pain Market Share (%), By End-user, 2017-2031F
Figure 106. China Chronic Lower Back Pain Market, By Value, in USD Billion, 2017-2031F
Figure 107. China Chronic Lower Back Pain Market, By Volume, in Million Units, 2017-2031F
Figure 108. China Chronic Lower Back Pain Market Share (%), By Drug Class, 2017-2031F
Figure 109. China Chronic Lower Back Pain Market Share (%), By Route of Administration, 2017-2031F
Figure 110. China Chronic Lower Back Pain Market Share (%), By End-user, 2017-2031F
Figure 111. Japan Chronic Lower Back Pain Market, By Value, in USD Billion, 2017-2031F
Figure 112. Japan Chronic Lower Back Pain Market, By Volume, in Million Units, 2017-2031F
Figure 113. Japan Chronic Lower Back Pain Market Share (%), By Drug Class, 2017-2031F
Figure 114. Japan Chronic Lower Back Pain Market Share (%), By Route of Administration, 2017-2031F
Figure 115. Japan Chronic Lower Back Pain Market Share (%), By End-user, 2017-2031F
Figure 116. Australia Chronic Lower Back Pain Market, By Value, in USD Billion, 2017-2031F
Figure 117. Australia Chronic Lower Back Pain Market, By Volume, in Million Units, 2017-2031F
Figure 118. Australia Chronic Lower Back Pain Market Share (%), By Drug Class, 2017-2031F
Figure 119. Australia Chronic Lower Back Pain Market Share (%), By Route of Administration, 2017-2031F
Figure 120. Australia Chronic Lower Back Pain Market Share (%), By End-user, 2017-2031F
Figure 121. Vietnam Chronic Lower Back Pain Market, By Value, in USD Billion, 2017-2031F
Figure 122. Vietnam Chronic Lower Back Pain Market, By Volume, in Million Units, 2017-2031F
Figure 123. Vietnam Chronic Lower Back Pain Market Share (%), By Drug Class, 2017-2031F
Figure 124. Vietnam Chronic Lower Back Pain Market Share (%), By Route of Administration, 2017-2031F
Figure 125. Vietnam Chronic Lower Back Pain Market Share (%), By End-user, 2017-2031F
Figure 126. South Korea Chronic Lower Back Pain Market, By Value, in USD Billion, 2017-2031F
Figure 127. South Korea Chronic Lower Back Pain Market, By Volume, in Million Units, 2017-2031F
Figure 128. South Korea Chronic Lower Back Pain Market Share (%), By Drug Class, 2017-2031F
Figure 129. South Korea Chronic Lower Back Pain Market Share (%), By Route of Administration, 2017-2031F
Figure 130. South Korea Chronic Lower Back Pain Market Share (%), By End-user, 2017-2031F
Figure 131. Indonesia Chronic Lower Back Pain Market, By Value, in USD Billion, 2017-2031F
Figure 132. Indonesia Chronic Lower Back Pain Market, By Volume, in Million Units, 2017-2031F
Figure 133. Indonesia Chronic Lower Back Pain Market Share (%), By Drug Class, 2017-2031F
Figure 134. Indonesia Chronic Lower Back Pain Market Share (%), By Route of Administration, 2017-2031F
Figure 135. Indonesia Chronic Lower Back Pain Market Share (%), By End-user, 2017-2031F
Figure 136. Philippines Chronic Lower Back Pain Market, By Value, in USD Billion, 2017-2031F
Figure 137. Philippines Chronic Lower Back Pain Market, By Volume, in Million Units, 2017-2031F
Figure 138. Philippines Chronic Lower Back Pain Market Share (%), By Drug Class, 2017-2031F
Figure 139. Philippines Chronic Lower Back Pain Market Share (%), By Route of Administration, 2017-2031F
Figure 140. Philippines Chronic Lower Back Pain Market Share (%), By End-user, 2017-2031F
Figure 141. Middle East & Africa Chronic Lower Back Pain Market, By Value, in USD Billion, 2017-2031F
Figure 142. Middle East & Africa Chronic Lower Back Pain Market, By Volume, in Million Units, 2017-2031F
Figure 143. Middle East & Africa Chronic Lower Back Pain Market Share (%), By Drug Class, 2017-2031F
Figure 144. Middle East & Africa Chronic Lower Back Pain Market Share (%), By Route of Administration, 2017-2031F
Figure 145. Middle East & Africa Chronic Lower Back Pain Market Share (%), By End-user, 2017-2031F
Figure 146. Middle East & Africa Chronic Lower Back Pain Market Share (%), By Country, 2017-2031F
Figure 147. Saudi Arabia Chronic Lower Back Pain Market, By Value, in USD Billion, 2017-2031F
Figure 148. Saudi Arabia Chronic Lower Back Pain Market, By Volume, in Million Units, 2017-2031F
Figure 149. Saudi Arabia Chronic Lower Back Pain Market Share (%), By Drug Class, 2017-2031F
Figure 150. Saudi Arabia Chronic Lower Back Pain Market Share (%), By Route of Administration, 2017-2031F
Figure 151. Saudi Arabia Chronic Lower Back Pain Market Share (%), By End-user, 2017-2031F
Figure 152. UAE Chronic Lower Back Pain Market, By Value, in USD Billion, 2017-2031F
Figure 153. UAE Chronic Lower Back Pain Market, By Volume, in Million Units, 2017-2031F
Figure 154. UAE Chronic Lower Back Pain Market Share (%), By Drug Class, 2017-2031F
Figure 155. UAE Chronic Lower Back Pain Market Share (%), By Route of Administration, 2017-2031F
Figure 156. UAE Chronic Lower Back Pain Market Share (%), By End-user, 2017-2031F
Figure 157. South Africa Chronic Lower Back Pain Market, By Value, in USD Billion, 2017-2031F
Figure 158. South Africa Chronic Lower Back Pain Market, By Volume, in Million Units, 2017-2031F
Figure 159. South Africa Chronic Lower Back Pain Market Share (%), By Drug Class, 2017-2031F
Figure 160. South Africa Chronic Lower Back Pain Market Share (%), By Route of Administration, 2017-2031F
Figure 161. South Africa Chronic Lower Back Pain Market Share (%), By End-user, 2017-2031F
Figure 162. By Drug Class Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 163. By Route of Administration Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 164. By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 165. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023
Lift of Tables
Table 1. Pricing Analysis of Products from Key Players
Table 2. Competition Matrix of Top 5 Market Leaders
Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
Table 4. About Us - Regions and Countries Where We Have Executed Client Projects
Frequently Asked Questions
What are the regions covered in the final report for global chronic lower back pain market?
The major factors influencing the global chronic lower back pain market growth are the growing prevalence of lower back pain cases, growing emphasis on drug development for lower back pain management, and growing awareness about pain management.
What are the major drivers influencing the growth of global chronic lower back pain market?
What is the market size and growth rate of global chronic lower back pain market?
See Related Reports
Global Bone Densitometers Market Assessment, Opportunities and Forecast, 2017-2031F
There is an increased demand for dual-energy x-ray absorptiometry (DXA) in the global bone densitometers market. Also, increasing prevalence of osteoporosis, growing geriatric population, technological advancements, and collaborative research and new....Read More
Published on
May 2024
4,500
Global Medical Terminology Software Market Assessment, Opportunities and Forecast, 2017-2031F
Global medical terminology software market is expected to witness significant growth over the forecast period owing to an increase in measures for reducing clinical errors and rising investments towards the development of technologically advanced sol....Read More
Published on
May 2024
4,500
Global Legionella Testing Market Assessment, Opportunities and Forecast, 2017-2031F
Global legionella testing market will witness significant growth owing to the rapid expansion of the healthcare sector, increasing awareness about the importance of regular legionella testing, and rising prevalence of legionella related illnesses.....Read More
Published on
May 2024
4,500
Global Endoluminal Suturing Devices Market Assessment, Opportunities and Forecast, 2017-2031F
Global endoluminal suturing devices market is expected to witness significant growth over the forecast period owing to rise in the number of cases of gastrointestinal cancer and increasing preference for non-invasive procedures.....Read More
Published on
May 2024
4,500
Purchase Options
USD ($)
i
3,000
i
4,500
i
5,700
i
8,200
Tired of Searching?
Looking for Customization?
Some other doubt?
Need insights from a cohort?
REACH US
